[Therapeutic thrombocytapheresis in patients with myeloproliferative diseases with the cell separators Fresenius AS 104 and Cobe Spectra: biocompatibility and safety].
We studied biocompatibility, safety and efficiency of the two cell separators AS 104 (Fresenius) and Spectra (Cobe) during therapeutic thrombocytaphereses. Although some patients have very high platelet levels and coagulation as well as circulatory equilibrium is easily disturbed, no important activation of coagulation or complement was observed. In respect to patient's safety both cell separators performed very well.
Ullrich
H
H
Abteilung für Transfusionsmedizin und Immunhmatologic, Universitätskliniken Würzburg, BRD.
Kadar
J
J
Waxenberger
Y
Y
Hohe
R
R
Saueressig
C
C
Heyder
M
M
Wiebecke
D
D
D001672:Biocompatible Materials; D001780:Blood Coagulation Tests; D001798:Blood Proteins / Q000032:analysis; D003167:Complement Activation / Q000502:physiology; D004868:Equipment Failure; D004906:Erythrocyte Count; D006801:Humans; D007958:Leukocyte Count; D009196:Myeloproliferative Disorders / Q000097:blood / Q000628:therapy*; D010976:Platelet Count; D010983:Plateletpheresis / Q000295:instrumentation*; D013922:Thrombocytosis / Q000097:blood / Q000628:therapy
D001672:Biocompatible Materials; D001798:Blood Proteins
Therapeutische Thrombozytapheresen an Patienten mit myeloproliferativen Erkrankungen mit den Zellseparatoren Fresenius AS 104 und Cobe Spectra: Biokompatibilität und Sicherheit.